Chemotherapy for transarterial chemoembolization in patients with unresectable hepatocellular carcinoma

Table 2 Univariate and multivariate analysis for the factors that influence tumor progression

Factors	Univariate (P value)	Multivariate (P value)	Exp(B)	95%CI
Cirrhosis of the liver
Absent/Present	0.025	0.928	1.070	0.242-4.729
Pathological stage
I/II/III/IV	0.022	0.021	0.643	0.442-0.936
TACE Sessions
≤ 2/> 2	0.009	0.083	1.272	0.969-1.670
BCLC Stage
A/B/C	0.006	0.666	1.241	0.465-3.316
Number of Tumor
Single/Multiple	0.039	0.734	0.839	0.305-2.309
CLIP Score
≤ 2/> 2	0.013	0.466	0.822	0.485-1.392
Chemotherapy agent
CPT-11/GEM/Doxorubicin	0.020	0.648	0.869	0.474-1.591
PS score
1/2/2000	0.029	0.032	0.095	0.011-0.818

Exp(B) stands for relative risk (RR). TACE: Transarterial chemoembolization; BCLC: Barcelona Clinic Liver Cancer Group; CLIP: Cancer of the Liver Italian Program; CPT-11: Chemotherapeutic agent irinotecan; GEM: Gemcitabine.